Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Top Cited Papers
- 12 February 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (7), 622-631
- https://doi.org/10.1056/NEJMoa1803537
Abstract
Among patients with severe antineutrophil cytoplasmic antibody-associated vasculitis, plasma exchange did not reduce the incidence of death or end-stage kidney disease. A reduced-dose regimen of oral glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. Background More effective and safer treatments are needed for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Methods We conducted a randomized trial with a 2-by-2 factorial design to evaluate the use of plasma exchange and two regimens of oral glucocorticoids in patients with severe ANCA-associated vasculitis (defined by an estimated glomerular filtration rate of <50 ml per minute per 1.73 m(2) of body-surface area or diffuse pulmonary hemorrhage). Patients were randomly assigned to undergo plasma exchange (seven plasma exchanges within 14 days after randomization) or no plasma exchange (control group). Patients were also randomly assigned to follow either a standard-dose regimen or a reduced-dose regimen of oral glucocorticoids. Patients were followed for up to 7 years for the primary composite outcome of death from any cause or end-stage kidney disease (ESKD). Results Death from any cause or ESKD occurred in 100 of 352 patients (28.4%) in the plasma-exchange group and in 109 of 352 patients (31.0%) in the control group (hazard ratio, 0.86; 95% confidence interval [CI], 0.65 to 1.13; P=0.27). The results were similar in subgroup analyses and in analyses of secondary outcomes. We also assessed the noninferiority of a reduced-dose regimen of glucocorticoids to a standard-dose regimen, using a noninferiority margin of 11 percentage points. Death from any cause or ESKD occurred in 92 of 330 patients (27.9%) in the reduced-dose group and in 83 of 325 patients (25.5%) in the standard-dose group (absolute risk difference, 2.3 percentage points; 90% CI, -3.4 to 8.0), which met the criterion for noninferiority. Serious infections at 1 year were less common in the reduced-dose group than in the standard-dose group (incidence rate ratio, 0.69; 95% CI, 0.52 to 0.93), but other secondary outcomes were similar in the two groups. Conclusions Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD. A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. (Funded by the U.K. National Institute for Health Research and others; PEXIVAS Current Controlled Trials number, ; ClinicalTrials.gov number, .)Funding Information
- Health Technology Assessment Programme (HTA 08/56/04)
- U.S. Food and Drug Administration (FDA R01 FD003516)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR0573319)
- National Health and Medical Research Council (626939, 631731, APP1086192, APP1092957)
- Canadian Institutes of Health Research (159662, 211079)
- Ministère des Affaires Sociales et de la Santé (AOM11142)
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
- Terumo BCT
- Terumo BCT Mexico
- Fresenius Medical Care Australia
- Baxter Healthcare Pty Ltd
- Asahi Kasei Medical Co. Ltd.
This publication has 33 references indexed in Scilit:
- Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trialTrials, 2013
- Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysisRheumatology, 2011
- The Number of Patients and Events Required to Limit the Risk of Overestimation of Intervention Effects in Meta-Analysis—A Simulation StudyPLOS ONE, 2011
- Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysisAmerican Journal of Kidney Diseases, 2011
- Long-term patient survival in ANCA-associated vasculitisAnnals Of The Rheumatic Diseases, 2011
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Interventions for renal vasculitis in adults. A systematic reviewBMC Nephrology, 2010
- Experimental Autoimmune Vasculitis: An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic VasculitisThe American Journal of Pathology, 2009
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- Treatment of Polyarteritis Nodosa with Cortisone: Results After Three Years: Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity PanelBMJ, 1960